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Abstract
Background Plasma N-terminal pro-brain natriuretic
peptide (NT-proBNP) levels are elevated in patients with
secondary pulmonary hypertension and chronic lung dis-
ease with right ventricular overload. The aim of the present
study was to investigate the use of plasma NT-proBNP
levels as a prognostic marker of severe COPD with chronic
respiratory failure and latent pulmonary hypertension.
Methods Plasma NT-proBNP levels were measured in 61
patients with stable COPD. Plasma NT-proBNP levels, pul-
monary function, PaO2,a n dP a C O 2 levels and systolic pul-
monary artery pressure were compared according to COPD
severity. In addition, we examined correlations between
plasma NT-proBNP levels and pulmonary function, PaO2,
PaCO2, and systolic pulmonary artery pressure.
Results The levels of plasma NT-proBNP signiﬁcantly
increased in patients with stage IV and stage III COPD com-
pared to individuals with stage II COPD according to the
Global Initiative for Chronic Obstructive Lung Disease
(GOLD) classiﬁcation. The area under the receiver-operating
characteristic curve of plasma NT-proBNP for severe to very
severe COPD (FEV1\50%) was 0.707 (95% conﬁdence
interval [CI] 0.566–0.847, P = 0.008). Plasma NT-proBNP
levels signiﬁcantly correlated with %FEV1 (r =- 0.557;
P\0.001), arterial blood gas parameters such as PaCO2
(r = 0.476; P\0.001) and PaO2 (r =- 0.347; P = 0.031),
and systolic pulmonary artery pressure (r = 0.435; P =
0.001).
Conclusions Plasma NT-proBNP levels increased sig-
niﬁcantly with disease severity, progression of chronic
respiratory failure, and secondary pulmonary hypertension
in patients with stable COPD. These results suggest that
plasma NT-proBNP can be a useful prognostic marker to
monitor COPD progression and identify cases of secondary
pulmonary hypertension in patients with stable COPD.
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Introduction
Brain natriuretic peptide (BNP) was ﬁrst described in 1988
after being isolated from porcine brain [1]. However, this
proteinwassoonfoundtooriginatemainlyfromtheheartand
identiﬁed as a cardiac hormone. BNP is synthesized as a
prehormone (proBNP) composed of 108 amino acids. Upon
release into circulation it is cleaved into equal amounts of
biologically active 32-amino-acid BNP, which represents the
C-terminal fragment, and the biologically inactive 76-amino-
acid N-terminal fragment (NT-proBNP). The main stimulus
responsibleforincreasingBNPandNT-proBNPsynthesisand
secretion is myocardial wall stress. Furthermore, factors such
asmyocardialischemiaandendocrine(paracrine)modulation
byotherneurohormonesandcytokinesarealsoinvolved.The
half-life of BNP is 20 min, whereas NT-proBNP has a half-
life of120 min.This explainswhyNT-proBNP serum values
are approximately six times higher than BNP values, even
thoughbothmolecules are releasedinequimolar proportions.
Several large trials have found that the most frequent
cause of death among patients with COPD is cardiac, rather
thanrespiratory,complications[2,3].Secondarypulmonary
S. Y. Chi   E. Y. Kim   H. J. Ban   I. J. Oh  
Y. S. Kwon   K. S. Kim   Y. I. Kim   Y. C. Kim  
S. C. Lim (&)
Department of Internal Medicine, Chonnam National University
Hospital, 671 Jaebongro, Dongku, Kwangju 501-757, Korea
e-mail: lscmd@jnu.ac.kr
123
Lung (2012) 190:271–276
DOI 10.1007/s00408-011-9363-7hypertensionandcorpulmonalearealsoimportantcausesof
death and poor prognosis in COPD patients [4, 5], so early
detectionofpulmonaryhypertensionorcorpulmonalecould
be beneﬁcial in managing patients with COPD. BNP has
beenshowntobeusefulforthediagnosingpatientssuspected
of having heart failure [6, 7]. It is also well known that
plasma BNP levels are elevated in patients with secondary
pulmonary hypertension and chronic lung disease with right
ventricular overload [8–11]. However, few studies have
assessed the diagnostic utility of NT-proBNP for determin-
ing COPD severity and identifying chronic respiratory fail-
ure with the possibility of progression to secondary
pulmonary hypertension in patients with COPD. Therefore,
the aim of the present study was to investigate the use of
plasma NT-proBNP levels as a prognostic marker of severe
COPD with chronicrespiratory failure and latent pulmonary
hypertension.
Materials and Methods
Subjects
Patients diagnosed with COPD according to the American
ThoracicSociety(ATS)guidelines[12]wererecruitedforthis
study from January to December 2010. The inclusion criteria
wereahistoryofsmoking,aforcedexpiratoryvolumein1 sec
(FEV1)/forcedvitalcapacity(FVC)ratio\70%,andanFEV1
\80%ofthepredictedvalues.Differentconditions,including
advanced age, gender, body mass index (BMI), and noncar-
diac diseases such as pulmonary and renal dysfunction and
sepsis, might increase levels of plasma NT-proBNP [13–15]
so we excluded patients with respiratory disorders other than
COPD, pulmonary embolisms, infectious diseases, malig-
nancy, left ventricular dysfunction (systolic and/or diastolic
dysfunction),recentsurgery,andsevereendocrine,hepatic,or
renal dysfunction. At recruitment, the patients’ height and
weight were measured and body mass index was calculated
(kg/m
2). Disease severity was categorized according to
GOLDguidelinesandbasedonpost-bronchodilatorFEV1(%
predicted) values: stage I (mild), FEV1 C 80% predicted;
stageII(moderate),50% B FEV1\80%predicted;stageIII
(severe), 30% B FEV1\50% predicted; and stage IV (very
severe), FEV1\30% predicted or FEV1\50% predicted
plus chronic respiratory failure. This study protocol was
approved by the Chonnam National University Hospital
EthicsCommittee,andallsubjectsprovidedinformedwritten
consent prior to their participation.
Pulmonary Function Test
All pulmonary function tests were performed using a
Sensormedics 2400 Unit (Sensormedics, San Diego, CA,
USA) that met ATS standards [12]. Most pulmonary
function tests were performed on the same day as the
echocardiography and/or laboratory investigations. Three
technically acceptable measurements were obtained for
each patient, with the highest one included in the analyses.
Acceptable test results were deﬁned as those with a sharp
peak in the ﬂow curve and an expiratory duration greater
than 6 s. FEV1, FVC, and lung volume were expressed as a
percentage of the predicted values.
Echocardiography
Echocardiography was performed using a commercially
available instrument (Siemens Medical Solution, Malvern,
PA, USA) equipped with a 2.5-MHz probe. Tricuspid
regurgitation ﬂow was identiﬁed by color ﬂow Doppler
techniques, and the maximal jet velocity was recorded
from the parasternal or apical window with a continuous
wave Doppler echocardiographic probe. The trans-tricus-
pid pressure gradient (4P) could be calculated from the
maximum velocity of the tricuspid regurgitant jets (Vmax)
using the simpliﬁed form of the Bernoulli equation:
4P (mmHg) = Vmax (m/s) 9 4. An estimation of pul-
monary artery pressure was obtained by adding an estimate
of the right atrial pressure to 4P [16]. The left ventricular
ejection fraction (LVEF) was calculated using Simpson’s
rule (disc summation method) [17]. Left ventricular sys-
tolic dysfunction was deﬁned as LVEF\50%. LV dia-
stolic function was assessed by pulsed-wave Doppler mitral
inﬂow and pulmonary venous inﬂow, and the E/A velocity
ratio and ratio of systolic to diastolic forward ﬂow (S/D
ratio) were calculated. LV diastolic dysfunction was
deﬁned as impaired relaxation (grade I), pseudonormal
ﬁlling (grade II), or restrictive ﬁlling (grade III) by a
combination of transmitral and pulmonary ﬂow patterns
and left atrial volume indexes [18].
Laboratory Data
Blood samples for measuring plasma NT-proBNP levels
were obtained by collecting peripheral blood in tubes
containing ethylenediamine tetra-acetic acid (EDTA).
Measurements were performed within 2 h of collection
using a commercial kit (Roche Diagnostics Corp., India-
napolis, IN, USA) and an electrochemiluminescent method
with an Elecsys 2010 Automated Analyzer (Roche Diag-
nostics). The results are presented as pg/ml. Serum creat-
inine (SCr) levels assays were all performed with the Jaffe
method on a Hitachi Modular Pre-Analytics Plus system
(Roche Diagnostics) and expressed as mg/dl. For each
patient, renal function was evaluated by estimating glo-
merular ﬁltration rate (GFR) with the MDRD Study
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123equation [19]. Renal dysfunction was deﬁned as GFR\
60 ml/min/1.73 m
2.
Statistical Analysis
SPSS version 17.0 (SPSS Inc., Chicago, IL, USA) was used
for all statistical analyses. Data are expressed as the median
(25th to 75th percentiles). To examine differences between
the two groups, a Mann–Whitney test was used to compare
continuous variables. To compare differences among the
three groups, a Kruskal–Wallis test for continuous vari-
ables was performed. Correlation coefﬁcients were calcu-
lated with the Spearman rank test. Receiver-operating
characteristic (ROC) curve analysis was performed for
plasma NT-proBNP levels, with the severity of COPD
(GOLD stage II vs. GOLD stage III–IV) as the reference
standard. A P value of\0.05 was considered to be statis-
tically signiﬁcant.
Results
The baseline characteristics of the study population are
summarized in Table 1. Our study included 61 patients
with stable COPD. Twenty-one patients were classiﬁed as
having moderate COPD, 33 patients had severe COPD, and
7 patients were found to have very severe COPD when
stratiﬁed by ATS guidelines. There were no signiﬁcant
differences in age, gender, smoking history (pack-years),
BMI, LVEF, or GFR among subjects with different stages
of COPD.
The levels of plasma NT-proBNP were signiﬁcantly
lower in patients with stage II COPD [112.0 (75.0–160.0)
pg/ml] compared to individuals with stage III [151.0
(108.5–318.5) pg/ml, P = 0.018] and stage IV COPD
[250.0 (201.0–371.0) pg/ml, P = 0.027] according to
GOLD (Fig. 1a). However, no signiﬁcant differences in
plasma NT-proBNP levels were observed between patients
with stage III and stage IV disease (P = 0.310) (Fig. 1a). If
the patients were grouped as having moderate COPD
(FEV1 C 50%) and severe to very severe COPD
(FEV1\50%), the levels of plasma NT-proBNP were
signiﬁcantly lower in patients with moderate COPD [112.0
(75.0–160.0) pg/ml] compared to severe to very severe
COPD [166.0 (114.5–318.7) pg/ml, P = 0.008] (Fig. 1b).
A receiver-operating characteristic curve for plasma NT-
proBNP was performed for predicting severe to very severe
COPD (FEV1\50%) in all patients (Fig. 1c). The area
under the ROC curve of plasma NT-proBNP for severe to
very severe COPD was 0.707 (95% conﬁdence interval
[CI] 0.566–0.847, P = 0.008). Plasma NT-proBNP levels
signiﬁcantly correlated with pulmonary function parame-
ters such as %FEV1 (r =- 0.557; P\0.001) and arterial
blood gas parameters such as PaCO2 (r = 0.476;
P\0.001) and PaO2 (r = –0.347; P = 0.031). There was
also a signiﬁcant positive correlation between plasma NT-
proBNP concentrations and systolic pulmonary artery
pressure (r = 0.435; P = 0.001) (Fig. 2).
Discussion
In the present study, we speciﬁcally examined the potential
of plasma NT-proBNP levels in patients with stable COPD
to predict the severity of COPD, chronic respiratory failure,
and latent secondary pulmonary hypertension. Here we
report three major ﬁndings. First, we determined that
plasma NT-proBNP levels in patients with stable COPD
Table 1 Patient characteristics
Data are presented as median
(25th to 75th percentiles), unless
otherwise stated
M male, F female, BMI body
mass index, FEV1 forced
expiratory volume in 1 sec,
FVC forced volume capacity,
systolic Ppa systolic pulmonary
artery pressure, LVEF left
ventricular ejection fraction,
PaO2 arterial oxygen tension,
PaCO2 arterial carbon dioxide
tension, SCr serum creatinine,
GFR glomerular ﬁltration rate,
NT-proBNP N-terminal pro-
brain natriuretic peptide
a P\0.001,
b P = 0.034,
c P = 0.086,
d P = 0.023
Stage II Stage III Stage IV
Number 21 33 7
Gender (M/F) 16/5 25/8 6/1
Age (years) 74.0 (68.5–78.5) 74.0 (70.0–78.0) 73.0 (72.0–86.0)
BMI (kg/m
2) 21.0 (19.0–23.0) 20.0 (18.0–23.0) 23.0 (22.0–25.0)
Smoking (pack-years) 50 (20.0–56.2) 40 (25.0–50.0) 50 (17.5–110.0)
FEV1 (% predicted)
a 56.0 (53.0–64.5) 41.0 (34.0–46.5) 28.0 (15.0–29.0)
FVC (% predicted) 75.0 (59.5–86.0) 64.0 (43.0–76.5) 53.5 (40.7–74.7)
FEV1/FVC (%) 53.0 (42.0–58.5) 46.0 (38.5–57.5) 42.0 (28.0–61.0)
Systolic Ppa (mmHg) 39.0 (32.5–45.5) 42.0 (34.0–64.7) 45.0 (39.0–71.0)
LVEF (%) 63.2 (59.1–68.2) 63.7 (58.5–69.5) 66.1 (59.4–80.5)
PaO2 (mmHg)
b 84.5 (73.7–88.7) 72.0 (61.2–78.0) 73.0 (63.5–78.0)
PaCO2 (mmHg)
c 49 (44.5–54.7) 52 (48.0–57.0) 57 (51.0–59.0)
SCr (mg/dl) 0.6 (0.5–0.8) 0.7 (0.5–0.8) 0.8 (0.6–0.9)
GFR (ml/min/1.73 m
2) 73.8 (66.6–85.0) 68.1 (63.7–80.9) 73.5 (70.0–79.3)
NT–proBNP (pg/ml)
d 112.0 (75.0–160.0) 151.0 (108.5–318.5) 250.0 (201.0–371.0)
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123increased signiﬁcantly with disease severity. The levels of
plasma NT-proBNP were signiﬁcantly higher in patients
with stage IV and stage III COPD compared to individuals
with stage II COPD. Figure 1a shows that the level of
plasma NT-proBNP in patients with stage IV COPD is not
signiﬁcantly different from that of individuals with stage
III COPD. However, because only seven patients had stage
IV COPD, the difference of NT-proBNP between stage III
and stage IV did not reach statistical signiﬁcance most
likely because of a lack of statistical power, not because of
an actual lack of difference. In fact, Fig. 1a shows a linear
trend and Fig. 2a shows that for FEV1% below about 50%,
the variability around the ﬁtted regression line is quite
high. This result was also conﬁrmed when factors related to
age and gender were eliminated because it is known that
plasma NT-proBNP levels are affected by these factors.
Second, plasma NT-proBNP levels signiﬁcantly correlated
with chronic respiratory failure identiﬁed as decreased
PaO2 and increased PaCO2. Third, plasma NT-proBNP
levels were signiﬁcantly associated with systolic pulmon-
ary artery pressure.
The natriuretic peptide family consists of three peptides:
atrialnatriureticpeptide(ANP),BNP,andC-typenatriuretic
peptide (CNP). These neurohormones are released in
response to hemodynamic stress and help regulate intra-
vascular volume homeostasis. Circulating ANP and BNP
levels are elevated several-fold in patients with cor pulmo-
nale,evenintheabsenceofimpairedleftventricularfunction
[20]. Presumably, right atrial distention or overactivity in
response to increased right ventricular afterload stimulates
their release. Additionally, BNP is the predominant natri-
uretic peptide that modulates responses of the pulmonary
vasculaturetohypoxia[21].BNPmayplayanimportantrole
in attenuating the pressor response that is likely to occur in
humans in the presence of alveolar hypoxia.
The mechanism underlying high plasma NT-proBNP
levels in patients with stable COPD is not well understood.
There have been few studies that examined plasma NT-
proBNP levels in patients with stable COPD. A recent
study demonstrated that the overall diagnostic utility of
both NT-proBNP and BNP is lower for detecting heart
failure in patients with chronic dyspnea and COPD than in
individuals with acute dyspnea presenting at the emergency
department [22]. Stolz et al. [23] showed that plasma BNP
levels are signiﬁcantly elevated during acute exacerbation
of COPD compared to recovery. They hypothesized that
Fig. 1 a The levels of plasma
NT-proBNP were signiﬁcantly
lower in patients with stage II
COPD (moderate COPD)
compared to individuals with
stage III (severe) and stage IV
(very severe) COPD according
to GOLD classiﬁcation. b If the
patients are grouped as having
moderate COPD (FEV1 C 50%)
and severe to very severe COPD
(FEV1\50%), the levels of
plasma NT-proBNP are
signiﬁcantly lower in patients
with moderate COPD compared
to severe to very severe COPD.
Stage II, 50% B FEV1\80%
predicted; stage III,
30% B FEV1\50% predicted;
stage IV, FEV1\30%
predicted or FEV1\50%
predicted plus chronic
respiratory failure. a, b Data are
shown as box plots. Each box
represents the 25th to 75th
percentiles. Lines inside the
boxes represent the median.
Whiskers represent the 10th and
90th percentiles. c A receiver
operator characteristic (ROC)
curve of plasma NT-proBNP as
a predictor of severe to very
severe COPD (FEV1\50%) in
overall COPD patients
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123the elevation of BNP levels is at least partly due to
hypoxia-mediated contraction of small pulmonary arteri-
oles, resulting in increased pulmonary arterial pressure and
subsequent cardiac stress. However, this group failed to
show a signiﬁcant correlation between plasma BNP levels
and oxygen saturation, PaO2, PaCO2, or FEV1 [23].
In the present study, we observed signiﬁcant correlation
between plasma NT-proBNP levels and %FEV1, PaO2,
PaCO2, and systolic pulmonary artery pressure in patients
with stable COPD. This result can be explained by the fact
that decreased FEV1 may lead to increased air-trapping and
hyperinﬂation of the lung. Such hyperinﬂation is associated
with decreased cardiac function and may result in an
increase of plasma NT-proBNP. Another explanation
might be related to hypoxia or hypercapnia in patients with
COPD. Chronic hypoxia induced by the progression of
COPD could result in contraction of the small pulmonary
arterioles, resulting in increased pulmonary arterial systolic
pressure and increased plasma NT-proBNP levels.
In conclusion, we demonstrated that plasma NT-proBNP
levels signiﬁcantly increase with COPD severity, progres-
sion of chronic respiratory failure, and the presence of
secondary pulmonary hypertension in patients with stable
COPD. Our results suggest that plasma NT-proBNP can be
a useful prognostic marker of COPD progression. This
factor may also help identify cases of secondary pulmonary
hypertension in patients with stable COPD.
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